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ment (CBCM) in the context of the multi-centre NEURAPRO 
trial with monthly assessments of attenuated psychotic 
symptoms (APS). Using multilevel regressions and control-
ling for the initial severity of APS, the associations between 
(1) number of CBCM sessions received and severity of APS 
and (2) specific CBCM components and severity of APS were 
investigated.  Results: In month 1, a higher number of ses-
sions and more assessment of symptoms predicted an in-
crease in APS, while in month 3, a higher number of sessions 
and more monitoring predicted a decrease in the level of 
APS. More therapeutic focus on APS predicted an overall in-
crease in APS.  Conclusions: Our findings indicate that the 
association between intensity/content of CBCM and severity 
of APS in a sample of UHR participants depends on the 
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 Abstract 
 Background: Cognitive-behavioural therapy (CBT) is the 
first-choice treatment in clients with ultra-high risk (UHR) for 
psychosis. However, CBT is an umbrella term for a plethora 
of different strategies, and little is known about the associa-
tion between the intensity and content of CBT and the sever-
ity of symptomatic outcome.  Methods: A sample of 268 UHR 
participants received 6 months of CBT with case manage-
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length of time in treatment. CBCM may positively impact the 
severity of APS later in the course of treatment. Therefore, it 
would seem important to keep UHR young people engaged 
in treatment beyond this initial period. Regarding the spe-
cific content of CBCM, a therapeutic focus on APS may not 
necessarily be beneficial in reducing the severity of APS, a 
possibility in need of further investigation. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 The at-risk mental state or ultra-high risk (UHR) state 
describes individuals identified as being at enhanced risk 
of developing a first episode of psychosis, based on the 
presence of attenuated/short-lived psychotic symptoms 
or a significant drop in functioning in the context of a 
family history of psychosis. Since the introduction of the 
UHR criteria  [1] , considerable research attention has 
been directed towards the development of effective inter-
ventions to positively impact on the trajectory of the UHR 
state. Growing evidence suggests that psychological ther-
apies such as cognitive-behavioural therapy (CBT) may 
provide a safe and effective pre-emptive treatment option 
in UHR clients  [2–7] . While recent studies suggest that 
both psychological and pharmacological interventions 
reduce rates of transition to psychosis, CBT is, given the 
favourable risk-benefit ratio, considered the first-choice 
treatment in UHR groups  [8, 9] . 
 CBT-informed therapy is an umbrella term for a pleth-
ora of different strategies that has primarily been evalu-
ated as an overall “treatment package”  [10] which, in clin-
ical implementation, is carried out in a variety of forms 
 [11, 12] . CBT comprises various components such as psy-
choeducation, case formulation, cognitive challenging, or 
behavioural strategies. Little is known, especially in the 
field of at-risk mental states, about which components of 
CBT are in fact delivered and if there are specific CBT 
“ingredients” which may be more beneficial than others 
 [10, 13] . Furthermore, the effects of frequency or inten-
sity of CBT (i.e., number of sessions delivered) on treat-
ment outcome has only been partially investigated  [4] . 
The UK-based EDIE-2 trial showed that a higher number 
of sessions was associated with less attenuated psychotic 
symptoms (APS) at the 12-month follow-up  [4] . Second-
ary analyses based on this trial evaluated the presence of 
certain components in cognitive therapy from file notes 
and identified a greater treatment effect if case formula-
tion and homework were part of the therapy  [13] . An-
other study in clients with psychosis suggested that CBT 
was only beneficial for those who received the full 9 
months of CBT. CBT consisting exclusively of engage-
ment or assessment was not effective, and the therapy ap-
peared to have a detrimental effect on those who did not 
finish the intervention  [10] .
 Although there is evidence for an early (first 4 weeks) 
rapid response to CBT for depression  [14, 15] , little is 
known regarding the role of time in treatment in the UHR 
population. A qualitative study in psychosis investigating 
clients’ experiences of case formulation in CBT suggested 
that the reaction may be subject to change over time: 
some clients experienced it initially as confrontational; 
however, this improved over time in most clients  [16] .
 The current study addresses the need to identify effec-
tive components of CBT-informed therapy in UHR cli-
ents. This may help to develop more targeted and more 
effective treatment packages for future studies and clini-
cal implementation. 
 In the present study, a UHR treatment regimen con-
sisting of CBT delivered within a therapeutic framework 
of case management (CBCM) was evaluated. In CBCM, 
the case manager is a central clinician who both manages 
general aspects of the patient’s care and provides psycho-
therapy. 
 The aims of the present study were (1) to characterise 
the CBCM provided in this study and (2) to investigate 
whether the intensity of CBCM and/or specific CBCM 
components received predicted the severity of subse-
quent APS. 
 Based on the existing literature, it was hypothesised 
that a greater number of sessions would be associated 
with lower levels of subsequent symptomatology. Explor-
atory analyses regarding the specific CBCM components 
and time in treatment were also conducted. 
 Method 
 Study Design and Setting 
 This study is based on data from the NEURAPRO trial, a multi-
centre, double-blind randomised controlled trial investigating the 
effects of omega-3 polyunsaturated fatty acids versus placebo in 
UHR individuals (ACTRN 12608000475347)  [14, 15] . Overall, 304 
participants aged 13–40 years and meeting criteria for UHR status 
received either omega-3 polyunsaturated fatty acids together with 
CBCM, or placebo with CBCM. The total study period was 12 
months. All participants provided written informed consent prior 
to enrolment in the study. Details on the study methodology and 
results of the randomised controlled trial have been described in 
detail previously  [14, 15] . The study was presented to participants 
as a study of the effects of a nutritional supplement (omega-3 fatty 
acids) in addition to a psychosocial intervention (CBCM). In oth-
er words, the psychological intervention was presented as and 
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viewed by participants as integral to the intervention package. No 
significant differences in any demographic characteristics, clinical 
or functional outcomes, or CBCM variables were observed be-
tween the experimental and control groups at baseline or at the 
12-month follow-up  [15] . No significant differences in any of these 
variables were observed at medium term (3.5 years; manuscript in 
preparation). Therefore, CBCM across both groups was used for 
joint analysis in the current study. 
 Cognitive-Behavioural Case Management 
 CBCM consists of CBT within a case management framework 
and is globally implemented in numerous UHR clinics (for details, 
please see the PACE Clinic Manual: A Treatment Approach for 
Young People at Ultra High Risk for Psychosis  [16] ). All clinicians 
were extensively trained by senior psychologists according to a 
study-specific CBCM manual prior to study start. The manual con-
sists of the following modules: (1) stress management, (2) positive 
symptoms, (3) negative symptoms, (4) basic symptoms, and (5) 
comorbidity. In order to ensure treatment fidelity, regular (fort-
nightly) individual and group supervision was maintained. At the 
different sites, there was local supervision with a senior clinician as 
well as regular supervision with senior psychologists at the leading 
site (Orygen) via Skype. Sessions were audiotaped with client con-
sent. Session dates and CBCM content were recorded using a 
checklist completed by the clinician after every CBCM session. The 
checklist was divided into 13 CBCM components (see  Table 1 ). 
 Procedure  
 All participants received CBCM adapted to the participant’s level 
of need and symptom profile within the first 6 months of study en-
rolment. Symptomatic outcome was assessed at the end of each 
month. Since participants received on average less than 1 CBCM ses-
sion in months 5 and 6, and 80% of the sessions within the 6-month 
CBCM period occurred during the first 4 months, the current inves-
tigation focused on these first 4 months (month 1–4) of CBCM. 
 The following variables were created per individual: (1) num-
ber of sessions received (0, 1, 2, 3, 4 or more) and (2) number of 
times each specific component was received. 
 Outcome Measures 
 The severity of APS was operationalised as described by Mor-
rison et al.  [4] : using the Comprehensive Assessment of At-Risk 
Mental States (CAARMS  [17] ), we summed the scores of the prod-
uct of global rating scale score (0–6) and frequency (0–6) of the 
following 4 subscales: unusual thought content, non-bizarre ideas, 
perceptual abnormalities, and disorganised speech. 
 Statistical Methods  
 Due to the hierarchical structure of the data (repeated measures 
[level 1] nested within participants [level 2], and participants nest-
ed within study sites [level 3]), analyses were conducted using the 
procedure “mixed” for Stata 14.0 for linear mixed models, boot-
strapped with 500 replications. Additionally, we conducted a sen-
sitivity analysis including “completers” only. A completer was de-
fined as a participant who did not drop out, but completed all re-
search interviews. 
 Number of Sessions  
 To investigate the association between number of sessions re-
ceived and severity of APS while accounting for prior symptom-
atic levels, we applied the same procedure as described in Zilcha-
Mano et al.  [18] . The number of sessions during a month was used 
to predict the subsequent severity of APS (T) , while controlling for 
prior severity of APS (APS (T-1) ). Additionally, we controlled for 
depressive symptoms, gender, age, and number of sessions already 
 Table 1.  Components of cognitive-behavioural case management
Components % of sessions
Included in analysis
Monitoring 68.4
Stress management 51.3
Assessment of symptoms 48.2
Comorbidity 39.4
Negative symptoms 38.8
Homework 37.6
Positive symptoms 30.3
Case management 21.7
General information/psychoeducation 21.3
Basic symptoms 17.3
Not included in analysisa
Crisis management 14.4
Family work 14.4
Relapse prevention and termination 10.9
 a Excluded as these elements constituted less than 15% of the 
sessions.
 Table 2.  Baseline demographic and clinical data (n = 268)
Characteristic
Age, years 18.9 ± 4.35 (13 – 37) 
Gender
Female 146 (54)
Male 122 (46)
Ethnicity
Caucasian 216 (80)
Black or African American 7 (3)
Asian 35 (13)
Other 10 (4)
Education
Primary school 105 (39)
Secondary school, discontinued 49 (18)
Secondary school, completed 71 (27)
Trade or technical training 28 (11)
Undergraduate university course 14 (5)
Missing 1 (0)
APS 37.3 ± 16.89 (0 – 96)
MADRS 19.3 ± 8.92 (0 – 39) 
Values are n (%) or mean ± SD (range), as appropriate. APS, 
attenuated psychotic symptoms; MADRS, Montgomery-Asberg 
Depression Rating Scale.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.1
5.
16
 - 
3/
7/
20
18
 2
:3
6:
38
 P
M
 CBCM in Clients with Ultra-High Risk 
for Psychosis 
Psychother Psychosom 2017;86:292–299
DOI: 10.1159/000477551
295
received. As the association between the number of sessions and 
APS may depend on time in treatment, an interaction term be-
tween the number of sessions and the assessment time point (cat-
egorical, month 1–4) was introduced  [18] . Interaction terms were 
removed when not significant. 
 CBCM Components  
 The same model as described above was applied to investigate 
the association between specific CBCM components and the se-
verity of APS. 
 Components that may be related to outcome were initially 
identified in a univariate regression model unadjusted for the oth-
er components. Components that significantly predicted APS in 
the univariate models and components which constituted more 
than 15% of the sessions (see  Table 1 ) were included in the full, 
multivariate model, adjusted for the other components. As not all 
CBCM components were received by all participants, each model 
included only those participants who received the component at 
least once. 
 Results 
 Of the 304 participants randomised in the parent study 
 [15] , 268 participants (88%) had at least 1 symptom as-
sessment other than baseline, with CBCM checklist data 
on at least 1 session available. 
 Table 2 displays baseline demographic and clinical in-
formation. Participants received on average a total of 10.5 
sessions (SD 6.02, range 1–32). The number of sessions 
per month significantly decreased over time ( p < 0.001). 
The most prevalent CBCM components administered 
were “monitoring,” “stress management,” and “assess-
ment of symptoms” ( Table  1 ). The proportion of the 
components “general information/psychoeducation,” 
“monitoring,” “assessment of symptoms,” “positive 
symptoms,” “basic symptoms,” and “homework” de-
creased over time ( p < 0.01). The proportion of “relapse 
prevention and termination” increased with time ( p < 
0.001). All other components remained stable. 
 Number of Sessions 
 In predicting the severity of APS, the interaction be-
tween number of sessions and assessment time point 
(month 1–4) was significant (χ 2 (3) = 17.93,  p < 0.001). 
Using the Stata procedure Margins, the slopes per month 
were subsequently estimated. For month 1, there was a 
significant positive association between number of ses-
sions and severity of APS: more sessions significantly pre-
dicted  an increase  of APS (b = 1.61, SE = 0.59,  p = 0.007, 
95% CI: 0.44, 2.78). By month 3, a significant negative 
association between number of sessions and level of APS 
was observed: more sessions significantly predicted a  de-
crease  in APS (b = –1.23, SE = 0.46,  p = 0.008, 95% CI: 
–2.14, –0.32). In other words, while accounting for the 
initial severity of APS, each additional CBCM session at-
tendance was associated with a 1.6 point increase in sever-
ity of APS by the end of the first month, while during 
month 3, each additional session attended was associated 
with a 1.2 point reduction of severity of APS. Sensitivity 
analyses using completers only ( n = 207) yielded similar 
results: a positive association between number of sessions 
and APS in month 1 (b = 1.67, SE = 0.69,  p = 0.016, 95% 
CI: 0.32, 3.02), and a negative association in month 3 
(b = –1.20, SE = 0.46,  p = 0.009, 95% CI: –2.10, –0.30). 
 CBCM Components  
 “Family work,” “crisis management,” and “relapse 
prevention/termination” were a priori excluded from 
analyses because these components constituted less than 
15% of the CBCM sessions (see  Table 1 ). The components 
“psychoeducation,” “comorbidity,” “negative symp-
toms,” “homework,” and “basic symptoms” were not in-
cluded in the full model as they failed to show an associa-
tion with APS in the univariate models. 
 Table  3 provides the results of the full, multivariate 
models. Included were the components “case manage-
ment,” “monitoring,” “assessment of symptoms,” “stress 
management,” and “positive symptoms.” “Monitoring” 
and “assessment of symptoms” showed an interaction 
with time point, with a similar pattern to that seen for 
number of sessions. There was a positive association be-
tween the component “assessment of symptoms” and se-
verity of APS during the first month (i.e., more assess-
ment, more symptoms). For the component “monitor-
ing,” a negative association was observed for month 3 
(i.e., more monitoring, lower level of symptoms). “Stress 
management” and “case management” did not show a 
significant association with APS in the full model. The 
component “positive symptoms” demonstrated a positive 
association with APS (i.e., more focus on positive symp-
toms, more APS) throughout the treatment. 
 Discussion 
 Our study investigated the content and intensity of a 
CBCM regimen in UHR participants provided in the con-
text of the NEURAPRO trial, both descriptively as well as 
in association with APS. Our findings indicate that the ma-
jority of CBCM occurred within the first 4 months of the 
protocol and there was substantial variation in the number 
of sessions received (ranging from 1 to 32 sessions), prob-
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ably reflecting variation in the clients’ clinical presenta-
tions and varying levels of engagement. The most fre-
quently delivered elements of CBCM were “monitoring,” 
“stress management,” and “assessment of symptoms.” 
 In this study, we found that a greater number of ses-
sions predicted a higher level of APS at the end of the first 
4 weeks of treatment, an association which was reversed 
by month 3 (i.e., more sessions was associated with lower 
level of APS). To our knowledge, our findings are the first 
to indicate that the association between “intensity” of 
CBCM (i.e., number of sessions received) and level of APS 
may depend on time in treatment. These results appear to 
be robust, as the same pattern was observed when a sensi-
tivity approach was applied including completers only. 
 These novel findings may be interpreted in several 
ways. First of all, it is possible that the initial “unfavour-
able” CBCM-APS association is related to a form of re-
sponse bias. At the beginning of the treatment, the amount 
of psychoeducation regarding UHR is high, potentially 
leading to a change in how and what experiences are re-
vealed compared to the initial assessment. In other words, 
participants may be better informed, better able to de-
scribe, and potentially reveal new experiences they did 
not disclose at the initial assessment, leading to a higher 
rating of APS on the CAARMS for those who received 
more CBCM sessions. Alternatively, the positive associa-
tion between number of sessions and level of APS in the 
first 4 weeks may be driven by participants with increas-
ing APS receiving more sessions (i.e., an increase in clin-
ical contact in response to worsening symptoms). Simi-
larly, the negative association between number of ses-
sions and APS in month 3 may be driven by participants 
with decreasing APS receiving fewer sessions. However, 
the probability of this form of reverse causation has been 
reduced by controlling for the previous level of APS for 
every participant. 
 Conversely, and speculatively, it may be the case that at 
the very outset of treatment, CBCM is associated with an 
initial intensification of APS. In support of this, Dunn et 
al.  [10] identified a potential negative effect of CBT in pa-
tients with psychosis who stopped the treatment prema-
turely. Furthermore, a qualitative study on clients’ experi-
ence of CBT’s case formulation suggested a change over 
time, with some clients experiencing it as confrontational 
in the beginning, but with an improvement of those feel-
ings over time in most clients  [19] . Another qualitative 
study investigating the subjective experiences of UHR 
participants of the EDIE-2 trial indicated that many cli-
ents disclosed their unusual psychological experiences for 
the first time in their lives  [20] . Clients also suggested that 
talking about these experiences was challenging or diffi-
cult  [18, 19] . It is conceivable that initial confrontation 
 Table 3.  Results for the mixed model investigating the association between cognitive-behavioural case management component and 
level of attenuated positive symptoms
Component Component by time 
(interaction)
Coefficient 
(simple slopes, per month)
Coefficient
(overall main effect)
APS 
Case management
(n = 140)
χ2(3) = 5.51 – b = –0.23 (0.61) [–1.44, 0.97]
Monitoring
(n = 233)
χ2(3) = 11.06** Month 1: b = 0.36 (0.66) [–0.94, 1.66] –
Month 2: b = –1.04 (0.66) [–2.33, 0.25]
Month 3: b = –1.55 (0.60) [–2.73, –0.37]**
Month 4: b = 0.03 (0.83) [–1.58, 1.65]
Assessment
(n = 215)
χ2(3) = 8.01* Month 1: b = 1.49 (0.59) [0.33, 2.65]** -
Month 2: b = 0.27 (0.76) [–1.22, 1.75]
Month 3: b = –0.86 (0.85) [–2.52, 0.81]
Month 4: b = 1.29 (0.96) [–0.59, 3.16]
Stress management
(n = 229)
χ2(3) = 5.38 – b = –0.44 (0.45) [–1.32, 0.44]
Positive symptoms
(n = 174)
χ2(3) = 2.63 – b = 1.69 (0.60) [0.51, 2.87]**
 When interactions with time were not significant, the overall effect was estimated. Coefficients are expressed with SE in parentheses 
and 95% CI in square brackets. CBCM, cognitive-behavioural case management; APS, attenuated psychotic symptoms. *** p < 0.001; 
** p < 0.01; * p < 0.05.
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with these unusual experiences at the beginning of CBCM 
treatment is responsible for the initial unfavourable 
 CBCM-APS association. This is speculative and our re-
sults need to be replicated before firm conclusions can be 
drawn. It may reflect some traditional views of psycho-
therapy for psychosis  [10, 20] : talking about the content 
of psychotic experiences was sometimes discouraged from 
this perspective as it could lead to an aggravation or “in-
advertent collusion”  [21] . Most importantly, however, our 
results suggest that participants may start to benefit from 
more sessions of CBCM when they continue treatment. 
 A change in therapeutic alliance may also play a role 
in the observed association between CBCM intensity and 
APS. Therapeutic alliance is defined as the quality of the 
relationship between client and therapist and is regarded 
as playing a pivotal role in the outcome of psychotherapy 
 [22] . In a sample of people with acute first- or second-
episode psychosis, Goldsmith et al.  [20] showed that CBT 
may have detrimental effects (i.e., worse symptomatic 
outcome) when the therapeutic alliance is poor, and pos-
itive effects when the alliance is good. More importantly, 
improving the therapeutic alliance was associated with 
enhanced outcome  [20] . In the current study, the chang-
ing association between CBCM intensity and APS may be 
a result of an improving therapeutic alliance over time. 
Finally, it is also possible that, initially, CBT is somewhat 
difficult for this client group to engage with, possibly due 
to it being an overly formalised approach that may be 
challenging for young people, particularly when dis-
tressed and being oriented to a new service  [2] . This in-
terpretation would suggest that a therapeutic approach 
that emphasises engagement, “meeting the person where 
they are at,” and that is possibly more supportive and per-
son-centred in nature may be indicated in the very early 
phases of treatment for this group, before moving onto 
more concerted or focused CBT techniques.
 Regarding the CBCM components, only the compo-
nents “monitoring,” “assessment of symptoms,” and 
“positive symptoms” were significantly associated with 
severity of APS in the full model. “Monitoring” and “as-
sessment” followed the same pattern as number of ses-
sions: in interaction with time, “assessment of symptoms” 
was positively associated with APS (i.e., more assessment, 
higher level of symptoms) during the first month only, 
while this association changed its direction in month 3 
(without reaching significance). “Monitoring” was nega-
tively associated with APS in month 3 only (i.e., more 
monitoring, lower level of APS), and an investigation of 
the coefficients shows that also in this case, the associa-
tion changed its direction compared to month 1. 
 The finding regarding the component “positive 
symptoms” followed a different pattern. More focus on 
positive symptoms predicted a higher level of APS across 
the investigated intervention period (i.e., no interaction 
with time). Again, this finding can be interpreted in a 
number of ways. First, while we control for level of APS 
during the previous assessment, it is still possible that 
participants demonstrate increasing APS in the few 
weeks prior to a research assessment. This may be picked 
up by the clinician, who responds with an increased fo-
cus on APS during CBCM sessions. Conversely and 
speculatively, focusing on APS may not be beneficial in 
decreasing its level, in line with what is discussed and 
reviewed above. 
 The fact that most other components did not show sig-
nificant associations with symptomatic outcome may be 
due to a lack of power, and more research in larger sam-
ples is required. 
 As this study was a secondary analysis of the NEURA-
PRO trial and was not specifically designed to evaluate 
CBCM, it comes with the clear limitations of no control 
group (i.e., a group who received no CBCM or a different 
form of psychotherapy). Furthermore, components were 
not randomly assigned, but selected on the basis of par-
ticipant presentation. Although the current analytical ap-
proach (i.e., controlling for previous symptomatic levels) 
reduced the possibility of reverse causation, we cannot 
ascertain cause and effect. That is, symptomatic levels 
may be impacted by CBCM, and CBCM may be impacted 
by participant presentation, or both. Furthermore, it is 
likely that the different components may interact in im-
pacting on symptomatic levels and there may be order 
effects of the specific CBCM components. Moreover, we 
were not able to investigate certain components (i.e., cri-
sis management, family intervention) as these elements 
were delivered infrequently. However, our exploratory 
study can be used to generate hypotheses to be experi-
mentally tested in the future. In light of psychotherapeu-
tic interventions being a preferred option to medication 
in young people at risk of psychotic disorder, it is impor-
tant to identify the active ingredients or key components 
of CBT-informed therapies. Recommendations for fu-
ture studies are dismantling studies or trials randomising 
participants to components. Furthermore, it is important 
to measure therapeutic alliance over the course of CBT 
intervention and capture the detailed subjective experi-
ence of the participants. Understanding the specific struc-
ture (e.g., duration) and content (components) of CBT 
that is most effective for symptoms in this patient group 
can critically inform future treatment. 
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 Our findings, while preliminary, indicate that the as-
sociation between intensity/content of CBCM and sever-
ity of APS in a sample of UHR participants depends on 
time in treatment. CBCM may positively impact APS only 
later in the course of treatment, after an initial refractory 
phase. Therefore, it may be important for clinicians to 
keep UHR young people engaged in treatment beyond 
this initial period and to increase awareness and validation 
of the often potentially confronting and destabilising na-
ture of talking about and discussing APS for the first time. 
Alternatively, therapeutic approaches that emphasise en-
gagement, possibly more supportive and person-centred 
in nature, may be indicated in the very early phases of 
treatment for this group. Furthermore, a therapy focus on 
positive symptoms may not be beneficial for all clients 
throughout treatment. In line with the suggestions of 
Richardson and Doster  [23] , clinicians need to carefully 
balance treatment along 3 dimensions of baseline risk (i.e., 
the risk the person would be at without treatment), ex-
pected responsiveness to treatment, and possible vulner-
abilities (e.g., possible adverse effects) imposed by the 
treatment  [24] . Future studies that randomise participants 
to CBCM or CBT components are needed to replicate the 
current findings and ascertain cause and effect.
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